The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Ten Emerging Trends in the Epidemiology of Diabetic Retinopathy
Abstract
PURPOSE: Diabetes is a major public health problem affecting 415 million people worldwide. With the increasing prevalence of diabetes, diabetic retinopathy (DR) is emerging as the leading cause of avoidable blindness worldwide. METHODS: We reviewed previous and recent literature to provide an overview of emerging trends on the burden, epidemiology, risk factors, and prevention of DR. RESULTS: First, there is clear evidence of a global increase in the prevalence of diabetes. Second, there is a decline in the incidence of blindness due to DR, particularly in developed countries. Third, diabetic macular edema (DME) rather than proliferative diabetic retinopathy (PDR) is the increasingly common cause of visual impairment. Fourth, DR awareness remains patchy and low in most populations. Fifth, hyperglycemia remains the most consistent risk factor for DR in type 1 diabetes across different studies and populations. Sixth, in contrast, blood pressure is an important risk factor for DR in type 2 diabetes. Seventh, the relationship between dyslipidemia and DR remains unclear, with inconsistent results from different studies and trials. Eighth, the utility of predictive models incorporating multiple risk factors for assessing DR risk requires evaluation. Ninth, photographic screening of DR using tele-ophthalmology platforms is increasingly recognized as being feasible and cost-effective. Finally, DR prevention in low-resource settings cannot follow models developed in high-resource countries and requires different strategies. CONCLUSIONS: The ten trends we observed in the current review may guide planning of public healthcare strategies for the management of DR and prevention of blindness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Global prevalence and major risk factors of diabetic retinopathy
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1909 · Cited by 4,985 · cited 16×
“In Tokyo, 32% of those with type 2 diabetes were unaware of their DR status.59 In Singapore, while 90% of those with diabetes were aware of their diabetic status, more than 80% of those with DR were unaware of their DR status, including 25% of those with sight-threatening DR.60 Few studies have documented awareness of…”
BackgroundInfluentialSelf-citationGlucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“In addition, an increased risk of death due to cardiovascular causes was reported with intensive glycemic control in the ACCORD and the Veterans Affairs Diabetes trials.(89)”
BackgroundGlobal estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642 · cited 2×
“The total number of persons with diabetes continues to increase worldwide from 135 million in 1995,(25) to 171 million in 2000,(26) to 415 million in 2015.(1) This number is projected to increase dramatically to 642 million by 2040,(27)”
BackgroundMultifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Hu, F. B. (2011) · Diabetes Care · doi:10.2337/dc11-0442 · Cited by 1,954 · cited 1×
“factors of DR, including hypertension and high cholesterol, are on the rise in developing countries such as China and India,(39,40) it will be important to investigate the trend of DR in these countries.(39,41,42)”
BackgroundMechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Effects of medical therapies on retinopathy progression in type 2 diabetes
The ACCORD Study Group and ACCORD Eye Study Group (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001288 · Cited by 1,311
Prevalence of Diabetic Retinopathy in the United States, 2005-2008
Zhang, X., Saaddine, J. B., Chou, C.-F., Cotch, M. F., Cheng, Y. J., Geiss, L. S., Gregg, E. W., Albright, A. L., Klein, B. E. K., & Klein, R. (2010) · JAMA · doi:10.1001/jama.2010.1111 · Cited by 1,196 · cited 1×
“more common cause of vision loss in persons with type 2 diabetes.(43) In the WESDR, the overall prevalence of DME was shown to be 11.”
BackgroundStratton, I. M., Kohner, E. M., Aldington, S. J., Turner, R. C., Holman, R. R., Manley, S. E., & Matthews, D. R. (2001) · Diabetologia · doi:10.1007/s001250051594 · Cited by 1,019
Renal and retinal effects of enalapril and losartan in type 1 diabetes
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808400 · Cited by 791 · cited 1×
“Renin-Angiotensin System Study, treatment with ACE inhibitors, enalapril and losartan, was reported to reduce retinopathy progression by 70% after 5 years of follow-up.(102) In the ADVANCE Preterax and Diamicron MR Controlled Evaluation Retinal Measurement Study, while lowering BP with an ACE”
MethodWANG, P. (1993) · The Lancet · doi:10.1016/0140-6736(93)90816-y · Cited by 446
Sjølie, A. K., Klein, R., Porta, M., Orchard, T., Fuller, J., Parving, H. H., Bilous, R., & Chaturvedi, N. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61411-7 · Cited by 435 · cited 1×
“pathy and 35% reduction in progression of retinopathy in personswith type 1 diabetes, and 34% increase in regression of retinopathy in those with type 2 diabetes.(100,101) In the”
BackgroundHemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T., Hemmingsen, C., & Wetterslev, J. (2011) · BMJ · doi:10.1136/bmj.d6898 · Cited by 386
Mansberger, S. L., Sheppler, C., Barker, G., Gardiner, S. K., Demirel, S., Wooten, K., & Becker, T. M. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.1 · Cited by 177
Cheng, Y. J., Gregg, E. W., Geiss, L. S., Imperatore, G., Williams, D. E., Zhang, X., Albright, A. L., Cowie, C. C., Klein, R., & Saaddine, J. B. (2009) · Diabetes Care · doi:10.2337/dc09-0440 · Cited by 157
Prevalence of diabetic macular oedema and related health and social care resource use in England
Minassian, D. C., Owens, D. R., & Reidy, A. (2012) · British Journal of Ophthalmology · doi:10.1136/bjo.2011.204040 · Cited by 58
Primary prevention of diabetic retinopathy with fibrates: A retrospective, matched cohort study
Morgan, C. L., Owens, D. R., Aubonnet, P., Carr, E. S. M., Jenkins-Jones, S., Poole, C. D., & Currie, C. J. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-004025 · Cited by 31
Cited by
Guidelines on Diabetic Eye Care
Wong, T. Y., Sun, J., Kawasaki, R., Ruamviboonsuk, P., Gupta, N., Lansingh, V. C., Maia, M., Mathenge, W., Moreker, S., Muqit, M. M. K., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.04.007 · Cited by 839
Self-citationDiabetic retinopathy: Looking forward to 2030
Tan, T.-E., & Wong, T. Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1077669 · Cited by 511
Self-citationWong, T. Y., & Sabanayagam, C. (2020) · Ophthalmologica · doi:10.1159/000502387 · Cited by 310
Self-citationvan der Heijden, A. A., Abramoff, M. D., Verbraak, F., van Hecke, M. V., Liem, A., & Nijpels, G. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13613 · Cited by 296
“The prevalence of referable retinopathy in this population is small, which limits comparison to other populations with higher disease prevalence (Sabanayagam et al. 2016).”
BackgroundGlycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging
Fournet, M., Bonté, F., & Desmoulière, A. (2018) · Aging and disease · doi:10.14336/ad.2017.1121 · Cited by 291
Metadata
- Authors
- Sabanayagam, C., Yip, W., Ting, D. S. W., Tan, G., & Wong, T. Y.
- Venue
- Ophthalmic Epidemiology
- Publisher
- Informa UK Limited
- Published
- 2016-06-29
- Volume
- 23
- Issue
- 4
- Pages
- 209-222
- ISSN
- 0928-6586 (ISSN-L)
- 1744-5086
- OpenAlex
- W2466029418
- Cited by
- 159
- References
- 22
- FWCI
- 13.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.